Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 2,300 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Induction Phase Clear all
Active, not recruiting Phase 2 Interventional Results available

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT05500092
View directory record Official record
Conditions
Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Interventions
Nivolumab, (8gy x 3), Platinum Doublet
Drug · Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
4
States / cities
St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Phase 1 Interventional

IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

NCT04372433
View directory record Official record
Conditions
AML With Monocytic Differentiation, CMML
Interventions
IO-202, IO-202 and Azacitidine, IO-202 and Azacitidine + Venetoclax
Biological
Lead sponsor
Immune-Onc Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
14
States / cities
Davis, California • Duarte, California • Irvine, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC

NCT00616109
View directory record Official record
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
sunitinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 27, 2026, 10:59 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Fat Reduction Induced by Magnetic Device - Ultrasonographic Evaluation

NCT03537716
View directory record Official record
Conditions
Fat Burn
Interventions
Treatment with High Intensity Focused ElectroMagnetic system
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
22 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
New York, New York • Langhorne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Results available

Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

NCT03298984
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Alvocidib, Cytarabine, Daunorubicin
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Not applicable Interventional Results available

Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG

NCT01432626
View directory record Official record
Conditions
Stress Induced Cardiomyopathy
Interventions
I-123 radiolabeled metaiodobenzylguanidine cardiac imaging
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 27, 2026, 10:59 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab

NCT02436993
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Carboplatin, Paclitaxel, Bevacizumab, Trastuzumab, Pertuzumab
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2036
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration

NCT02401945
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
DE-120, Aflibercept
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
50 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Walnut Creek, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 27, 2026, 10:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia

NCT01876953
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
cytarabine, idarubicin, dasatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors

NCT00062439
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, docetaxel, etoposide, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
154
States / cities
Mobile, Alabama • Fort Collins, Colorado • Jacksonville, Florida + 97 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Early Phase 1 Interventional Results available

Extending taVNS Paired With Infant CIMT Into a Home-Based Setting

NCT05857527
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Custom EMG triggered Soterix taVNS stimulation with CIMT therapy in lab, Custom EMG triggered Soterix taVNS stimulation with CIMT therapy in home
Combination Product
Lead sponsor
Medical University of South Carolina
Other
Eligibility
6 Months to 18 Months
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

NCT01767129
View directory record Official record
Conditions
Dyskinesia, Parkinson's Disease
Interventions
AVP-923-45, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation

NCT01665677
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Atorvastatin calcium
Drug
Lead sponsor
Mehdi Hamadani
Other
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Morgantown, West Virginia • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)

NCT01997229
View directory record Official record
Conditions
Refractory Generalized Myasthenia Gravis
Interventions
Eculizumab, Placebo
Biological · Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
41
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Phase 1 Interventional

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

NCT00091143
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
gp100 antigen, incomplete Freund's adjuvant, keyhole limpet hemocyanin, fludarabine phosphate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Providence Cancer Center, Earle A. Chiles Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 27, 2026, 10:59 AM EDT
Terminated Not applicable Interventional Results available

Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer

NCT00070317
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage I Cervical Cancer
Interventions
Isosulfan Blue, Lymph Node Mapping, Lymphangiography, Methylene Blue, Radionuclide Imaging, Sentinel Lymph Node Biopsy, Technetium Tc-99m Sulfur Colloid, Therapeutic Conventional Surgery
Drug · Procedure · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neuraxial Versus Systemic Analgesia for Latent Phase Labor Effect on Rate of Operative Delivery

NCT00380978
View directory record Official record
Conditions
Labor Pain, Pregnancy
Interventions
combined spinal epidural analgesia, late analgesia (systemic)
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,026 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor

NCT00582933
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Allogeneic Marrow Transplant
Interventions
BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 54 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)

NCT01074047
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Conventional Care Regimen
Drug
Lead sponsor
Celgene
Industry
Eligibility
65 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Phase 2 Interventional

Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer

NCT00314678
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal Cancer
Interventions
Topotecan, Cisplatin, Paclitaxel
Drug
Lead sponsor
John P. Fruehauf
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia

NCT03844997
View directory record Official record
Conditions
Acute Myeloid Leukemia, AML
Interventions
Palcociclib, CPX-351
Drug
Lead sponsor
Sudipto Mukherjee, MD, PhD, MPH
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 27, 2026, 10:59 AM EDT
Withdrawn Phase 2 Interventional

Garlic in Hyperlipidemia Caused by HAART

NCT00029250
View directory record Official record
Conditions
HIV Infections, Hypercholesterolemia, Hypertriglyceridemia, Hyperglycemia
Interventions
Garlic powder standardized to allicin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 27, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

NCT00462943
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Omacetaxine mepesuccinate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
8
States / cities
Los Angeles, California • Beech Grove, Indiana • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2021 · Synced Oct 27, 2026, 10:59 AM EDT
Recruiting Phase 3 Interventional

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

NCT07577843
View directory record Official record
Conditions
Crohn Disease
Interventions
JNJ-78934804, Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
22
States / cities
Anaheim, California • Chula Vista, California • Los Alamitos, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 27, 2026, 10:59 AM EDT